Utpal Koppikar is the Chief Financial Officer of Atara Biotherapeutics, a position he has held since joining the company in June 2018. In this role, Utpal oversees Finance, Information Technology, and Investor Relations. Through a commitment to Atara’s mission of transforming the lives of patients with serious medical conditions, Utpal’s organization helps enable the advancement of our investigational medicines to commercialization.
Prior to his tenure with Atara, Utpal held several senior financial leadership positions at Gilead Sciences, including Vice President of Corporate and Operations Finance, in which he was responsible for R&D, corporate, G&A, process development and manufacturing, and strategic sourcing. During his time there, he led the three-year financial planning process and financial integration of Kite Pharma, upon that company’s acquisition by Gilead in October 2017. Before that, Utpal played a key role as Gilead’s Vice President of Finance Europe, Middle East and Australia, in partnering with the commercial division for multiple product launches in the HIV and HCV franchises.
Prior to Gilead, Utpal served in multiple finance roles of increasing responsibility at Amgen. He began his career at Honeywell Aerospace (formerly AlliedSignal).
Utpal earned his B.S. in aerospace engineering at the University of Maryland and received a M.S. in aeronautical and astronautical engineering from Stanford University. He also holds an MBA in finance and marketing from The Anderson School at UCLA.
Away from work, Utpal enjoys spending time with his wife and two teenagers, traveling, and mentoring aspiring young aviators.
What is Utpal Koppikar's net worth?
The estimated net worth of Utpal Koppikar is at least $130,059.68 as of March 2nd, 2023. Mr. Koppikar owns 181,978 shares of Atara Biotherapeutics stock worth more than $130,060 as of April 24th. This net worth evaluation does not reflect any other assets that Mr. Koppikar may own. Learn More about Utpal Koppikar's net worth.
How do I contact Utpal Koppikar?
Has Utpal Koppikar been buying or selling shares of Atara Biotherapeutics?
Utpal Koppikar has not been actively trading shares of Atara Biotherapeutics over the course of the past ninety days. Most recently, Utpal Koppikar sold 6,871 shares of the business's stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $3.63, for a transaction totalling $24,941.73. Following the completion of the sale, the chief financial officer now directly owns 181,978 shares of the company's stock, valued at $660,580.14. Learn More on Utpal Koppikar's trading history.
Who are Atara Biotherapeutics' active insiders?
Are insiders buying or selling shares of Atara Biotherapeutics?
During the last year, Atara Biotherapeutics insiders bought shares 2 times. They purchased a total of 279,020 shares worth more than $64,384.40. During the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 184,801 shares worth more than $237,993.35. The most recent insider tranaction occured on March, 4th when CEO Pascal Touchon sold 24,844 shares worth more than $17,887.68. Insiders at Atara Biotherapeutics own 4.5% of the company.
Learn More about insider trades at Atara Biotherapeutics. Information on this page was last updated on 3/4/2024.
